Generic placeholder image

Clinical Cancer Drugs

Editor-in-Chief

ISSN (Print): 2212-697X
ISSN (Online): 2212-6988

Case-Report: Folfoxiri Plus Bevacizumab in “Poor-Risk” Liver-Only Metastatic Colorectal Cancer: Case Report and State-of-the-Art

Author(s): Lisa Salvatore, Fotios Loupakis, Andrea Ciarlo, Chiara Cremolini, Camilla Comin, Marta Schirripa, Luca Messerini, Federica Marmorino, Carlotta Antoniotti and Alfredo Falcone

Volume 1 , Issue 1 , 2014

Page: [78 - 83] Pages: 6

DOI: 10.2174/2212697X0101131204152941

Abstract

A 61-year-old white man presented with a stenosing tumour of the right colon and a large hepatic metastasis measuring 90 mm in its largest diameter, judged not suitable for immediate resection. He underwent right hemicolectomy and received 12 cycles of treatment with 5-fluorouracil/leucovorin, oxaliplatin and irinotecan (FOLFOXIRI) plus bevacizumab. According to Response Evaluation Criteria in Solid Tumors (RECIST criteria), he achieved a partial response that allowed a secondary radical hepatic resection. Pathologic examination of the liver specimen showed the absence of residual tumour cells: a pathologic complete response (pCR) was achieved. In this case, an intensive up-front treatment (i.e. the combination of FOLFOXIRI plus bevacizumab) produced the pCR of a liver metastasis from colorectal cancer despite its initial large dimension while confirming the possible discrepancy between radiologic assessment and pathological findings.

Keywords: Metastatic colorectal cancer, liver resection, preoperative chemotherapy, bevacizumab, FOLFOXIRI, complete pathologic response.


© 2022 Bentham Science Publishers | Privacy Policy